Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is heading past high of day. just MMs getting refilled while shorting it down. classic manipulation with no oversight.
sellers letting the shorts scare them
Getting ready to explode the other way. Watch! Recoil coming!
yeah but the wrong way.
i expected the lunch move at 12.. guess it came a lil early
CHFS wayyyyy oversold!
Also, big catalysts here, both fundamental and technical.
Investors are forward looking. Folks are encouraged by FDA giving the green light. Financially company on solid footing.
Shorts do not like HIGH VOLUME, SUPER LOW FLOATERS!!!!!
Indeed! They have cash to fund operations through Q1 2018! "Completed a warrant exercise agreement to incent exercise of warrants for cash which netted approximately $1.8 million in cash proceeds. Subsequent to quarter end, completed an underwritten public equity offering for net proceeds of approximately $8.1 million, following which we believe we have sufficient cash to fund our operations through the first quarter of 2018."
When it's this easy you know it's going much higher:)
Soooo... how many times was the float traded in a hr lol.... only going higher
CHF Solutions' Aquadex FlexFlow(R) Aquapheresis System Receives FDA IDE Approval for Clinical Study for Pediatric Use
1 day 3 hours 19 minutes ago - DJNF
CHF Solutions' Aquadex FlexFlow(R) Aquapheresis System Receives FDA IDE Approval for Clinical Study for Pediatric Use
EDEN PRAIRIE, Minn., June 29, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that researchers in the Stanford University School of Medicine's Department of Pediatrics have received FDA Investigational Device Exemption (IDE) approval to conduct a clinical study to evaluate the safety and effectiveness of CHF Solutions' Aquadex FlexFlow Aquapheresis System for diuretic-resistant fluid overload in children with acute decompensated heart failure. The randomized multi-center, non-blinded clinical study will assess up to 45 children and young adults ages 6 months to 21 years with heart failure and diuretic-resistant fluid overload. Heart failure is the leading cause of death in children with cardiomyopathy and congenital heart disease.
The study seeks to determine whether Aquapheresis therapy is associated with greater weight loss and a non-inferior rate of renal dysfunction compared to optimal medical therapy. In addition, the impact on heart failure symptoms using a novel pediatric heart failure symptoms score developed by the investigators, adverse outcomes and the need for medical management will be evaluated as secondary endpoints. The study is being led by Stanford's Christopher Almond, Associate Professor of Pediatrics (Cardiology), and David Kwiatkowski, Clinical Assistant Professor of Pediatrics (Cardiology).
"We are pleased that the researchers have received FDA approval to proceed with this IDE study," said John Erb, Chairman and CEO of CHF Solutions. "Given the limitations of patient unresponsiveness to diuretic therapies over time, our solution represents a potentially transformative future standard of care. We look forward to the clinical data results and to continuing our efforts to provide patients with additional treatment options for the treatment of heart failure," Mr. Erb concluded.
With today's news, trending back to $8.00+
CHFS
CHFS is a great $$$$$ opportunity.
srsc too, low float, playing both now....heads up
looking good here w support and breaking resit....
CHFS > SUPER LOW FLOAT!!!!!
This one will be epic, FDA news, low floater and most of float locked up yesterday. Float so small even little guys can lock it down.. 2s en route!
another multi day runner like AVEO and SPEX
You too!!, thx.
have a good day and 4th holiday bro
same On DXt$ here
I looked at it a few days ago thanks, focusing on otc now as I traded MAR$ few times and only holding Dxt$ for now.
Thanks
Yup great play guys $$
CHFS...$1.37...great move in pre market...
Sorry to early, 1.3 and 1.6.
3.6 if I recall,lower 3.3.
And what is that?
I like it to fill the upper gap tomorrow .
Beauty from 75 alert...looking to fill that gap down on a gappa tomorrow...
So many got in over .90. It will have to go a bit higher to make dumping profitable. Unless you bought a bunch of shares at .10 last week people may stay in a little longer.
Tomorrow I'm jumping in with $1.5k
True but i would not play this as a long term. This is a day trade at best.
Tiny tiny float + green light from FDA = perfect storm:)
This is not fda approval for a product, this is to start clinical trials.
https://www.streetinsider.com/Corporate+News/CHF+Solutions+%28CHFS%29+Granted+FDA+IDE+Approval+for+Clinical+Study+Aquadex+FlexFlow+Aquapheresis+System+for+Pediatric+Use/13056574.html
FDA approval for clinical trials no products were actually FDA approved this is a pump and dump. What a turd of a stock.
Load now while it's under a buck
Imo it's about to fly
Followers
|
65
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1655
|
Created
|
07/06/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |